InnoCare Pharma Limited (HKG:9969)
Hong Kong
· Delayed Price · Currency is HKD 12.13
+0.35 (2.97%)
Mar 10, 2026, 11:25 AM HKT
InnoCare Pharma Revenue
InnoCare Pharma had revenue of 383.89M CNY in the quarter ending September 30, 2025, with 38.09% growth. This brings the company's revenue in the last twelve months to 1.43B, up 58.75% year-over-year. In the year 2024, InnoCare Pharma had annual revenue of 1.01B with 36.68% growth.
Revenue (ttm)
1.43B CNY
Revenue Growth
+58.75%
P/S Ratio
15.16
Revenue / Employee
1.21M CNY
Employees
1,176
Market Cap
23.64B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PegBio | -4.25M |
| Genscript Biotech | 6.50B |
| Duality Biotherapeutics | 2.38B |
| Shanghai Junshi Biosciences | 2.78B |
| Zai Lab | 3.58B |
| Ascentage Pharma Group International | 428.02M |
| Biocytogen Pharmaceuticals (Beijing) | 1.53B |
| Keymed Biosciences | 955.73M |